The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status
Abstract
Background Management of early-stage breast cancer in young women with mutations in BRCA1 or BRCA2 remains controversial. This study assessed the long-term risks of ipsilateral and contralateral breast cancer in a cohort of young women who underwent breast-conserving surgery followed by radiotherapy. Methods Between 1975 and 1998, 290 women with breast cancer diagnosed at age 42 years or younger underwent lumpectomy followed by radiotherapy at our hospital. We recruited 127 of these women for complete sequencing of BRCA1 and BRCA2. Demographic, clinical, pathological, and outcome data were recorded. The primary endpoints were rates of ipsilateral and contralateral breast cancer, in relation to germline BRCA1/2 status. Findings 105 women were classified as having sporadic disease (94 with wild-type or known polymorphisms and 11 with variants of unclear significance) and 22 as having genetic predisposition (deleterious mutations in BRCA1 [15] or BRCA2 [seven]). At 12 years of follow-up, the genetic group had significantly higher rates of ipsilateral (49% vs 21%, p=0.007) and contralateral events (42% vs 9%, p=0.001) than the sporadic group. The majority of events were classified as second primary tumours. No patient in the genetic group had undergone oophorectomy or was taking prophylactic agents such as tamoxifen. Interpretation Patients with germline mutations in BRCA1 or BRCA2 have a high risk of developing late ipsilateral and contralateral second primary tumours. With brea…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The results of the two non-matched cohort studies in Table 4 are contradictory, no significant difference being found in the Robson et al. study unlike in the Haffty et al. study of a subgroup of 127 patients under 42 years of age [9, 37].”
From Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature (2010) · cites this paper as [37]
In the citing paper
“All studies of BRCA1 and/or BRCA2 mutation carriers so far have reported an increased incidence of contralateral breast cancer [9, 15, 28-30, 37, 38, 40].”
From Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature (2010) · cites this paper as [37]
In the citing paper
“Haffty et al. [37] recorded a 42% rate in carriers versus a 9% rate in noncarriers ( P = 0.001) at 12 years.”
From Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature (2010) · cites this paper as [37]
In the citing paper
“In the latter study, the significantly higher ipsilateral recurrence rate in BRCA1/2 mutation carriers suggests that there might be an increase in the rate of second primary cancers after 10 years.”
From Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature (2010) · cites this paper as [37]
In the citing paper
“However, its safety in BRCA mutation carriers is a matter of debate, and several studies have compared ipsilateral tumour recurrence after breast-conserving treatment (BCT) in BRCA1 and BRCA2 mutation carriers and patients with sporadic cancers [9, 28-32, 37-41].”
From Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature (2010) · cites this paper as [37]
Citations
Cites
A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1
Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P. A., Harshman, K., Tavtigian, S., Liu, Q., Cochran, C., Bennett, L. M., Ding, W., et al. (1994) · Science · doi:10.1126/science.7545954 · Cited by 6,071
Identification of the breast cancer susceptibility gene BRCA2
Wooster, R., Bignell, G., Lancaster, J., Swift, S., Seal, S., Mangion, J., Collins, N., Gregory, S., Gumbs, C., Micklem, G., et al. (1995) · Nature · doi:10.1038/378789a0 · Cited by 3,645
Linkage of Early-Onset Familial Breast Cancer to Chromosome 17q21
Hall, J. M., Lee, M. K., Newman, B., Morrow, J. E., Anderson, L. A., Huey, B., & King, M.-C. (1990) · Science · doi:10.1126/science.2270482 · Cited by 2,550
Fisher, B., Bauer, M., Margolese, R., Poisson, R., Pilch, Y., Redmond, C., Fisher, E., Wolmark, N., Deutsch, M., Montague, E., et al. (1985) · New England Journal of Medicine · doi:10.1056/nejm198503143121101 · Cited by 2,194
Risks of cancer in BRCA1-mutation carriers
FORD, D. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91578-4 · Cited by 1,850
Veronesi, U., Saccozzi, R., Del Vecchio, M., Banfi, A., Clemente, C., De Lena, M., Gallus, G., Greco, M., Luini, A., Marubini, E., et al. (1981) · New England Journal of Medicine · doi:10.1056/nejm198107023050102 · Cited by 1,599
Fisher, B., Redmond, C., Poisson, R., Margolese, R., Wolmark, N., Wickerham, L., Fisher, E., Deutsch, M., Caplan, R., Pilch, Y., et al. (1989) · New England Journal of Medicine · doi:10.1056/nejm198903303201302 · Cited by 1,587
Efficacy of Bilateral Prophylactic Mastectomy in Women with a Family History of Breast Cancer
Hartmann, L. C., Schaid, D. J., Woods, J. E., Crotty, T. P., Myers, J. L., Arnold, P. G., Petty, P. M., Sellers, T. A., Johnson, J. L., McDonnell, S. K., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400201 · Cited by 1,423
van Dongen, J. A. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.14.1143 · Cited by 1,271
Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2
Sharan, S. K., Morimatsu, M., Albrecht, U., Lim, D.-S., Regel, E., Dinh, C., Sands, A., Eichele, G., Hasty, P., & Bradley, A. (1997) · Nature · doi:10.1038/386804a0 · Cited by 1,072
Research works printed but not linked: 1
- Seynaeve, 1998, Local recurrence following lumpectomy and irradiation in familial and hereditary vs sporadic breast cancer patients, Proc ASCO, 17, 119a
Cited by
Cancer Risks for BRCA1 and BRCA2 Mutation Carriers: Results From Prospective Analysis of EMBRACE
Mavaddat, N., Peock, S., Frost, D., Ellis, S., Platte, R., Fineberg, E., Evans, D. G., Izatt, L., Eeles, R. A., Adlard, J., et al. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djt095 · Cited by 951
Contralateral Breast Cancer in BRCA1 and BRCA2 Mutation Carriers
Metcalfe, K., Lynch, H. T., Ghadirian, P., Tung, N., Olivotto, I., Warner, E., Olopade, O. I., Eisen, A., Weber, B., McLennan, J., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.033 · Cited by 621
Pierce, L. J., Levin, A. M., Rebbeck, T. R., Ben-David, M. A., Friedman, E., Solin, L. J., Harris, E. E., Gaffney, D. K., Haffty, B. G., Dawson, L. A., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.7888 · Cited by 340
Self-citationHereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2
Petrucelli, N., Daly, M. B., & Feldman, G. L. (2010) · Genetics in Medicine · doi:10.1097/gim.0b013e3181d38f2f · Cited by 339
Tung, N. M., Boughey, J. C., Pierce, L. J., Robson, M. E., Bedrosian, I., Dietz, J. R., Dragun, A., Gelpi, J. B., Hofstatter, E. W., Isaacs, C. J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00299 · Cited by 332
Metadata
- Authors
- Haffty, B. G., Harrold, E., Khan, A. J., Pathare, P., Smith, T. E., Turner, B. C., Glazer, P. M., Ward, B., Carter, D., Matloff, E., Bale, A. E., & Alvarez-Franco, M.
- Affiliations
- Yale University (US)
- Corresponding author
- Haffty, Bruce G
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2002-04
- Volume
- 359
- Issue
- 9316
- Pages
- 1471-1477
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2081943419
- Cited by
- 307
- References
- 32
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 5 · 2023: 4 · 2022: 5 · 2021: 13 · 2020: 11 · 2019: 8 · 2018: 4 · 2017: 9 · 2016: 12 · 2015: 14 · 2014: 11 · 2013: 12 · 2012: 20
- FWCI
- 12.02
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Health Sciences › Medicine › Epidemiology › Multiple and Secondary Primary Cancers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- early-onset breast cancer, BRCA1, BRCA2, germline mutations, breast-conserving surgery, radiotherapy, ipsilateral breast cancer, contralateral breast cancer, second primary tumours, young women, bilateral mastectomy, chemoprophylaxis, genetic susceptibility
- MeSH terms
- Adult, Aged, Breast Neoplasms, Combined Modality Therapy, DNA Mutational Analysis, DNA, Neoplasm, Female, Humans, Middle Aged, Mutation, Neoplasm Recurrence, Local, Radiotherapy, Mastectomy, Segmental, Treatment Outcome, Age of Onset, Disease-Free Survival, BRCA1 Protein, BRCA2 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. https://app.cochat.ai/papers/10.1016/s0140-6736(02)08434-9
- The paper
- Haffty, B. G., Harrold, E., Khan, A. J., Pathare, P., Smith, T. E., Turner, B. C., Glazer, P. M., Ward, B., Carter, D., Matloff, E., Bale, A. E., & Alvarez-Franco, M. (2002). Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. The Lancet. https://doi.org/10.1016/s0140-6736(02)08434-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.